← FDA DRUG APPROVALS

FDA ANDA · ANDA218091

DAPAGLIFLOZIN AND METFORMIN

Sponsor: SINOTHERAPEUTICS INC

APPLICATION
ANDA218091
TYPE
ANDA
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)

Products

DAPAGLIFLOZIN AND METFORMINNone (Tentative Approval)
DAPAGLIFLOZIN || METFORMIN 1000MG · TABLET
DAPAGLIFLOZIN AND METFORMINNone (Tentative Approval)
DAPAGLIFLOZIN || METFORMIN 10MG · TABLET
DAPAGLIFLOZIN AND METFORMINNone (Tentative Approval)
DAPAGLIFLOZIN || METFORMIN 500MG · TABLET
DAPAGLIFLOZIN AND METFORMINNone (Tentative Approval)
DAPAGLIFLOZIN || METFORMIN 5MG · TABLET

Approval history

2025-05-08UNKNOWN · Original · standardTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →